Medical terminology

CipherHealth Unveils Next-Generation Patient Engagement Platform for Enhanced Personalization, Agility, and Scale to Improve Patient, Family, and Provider Experiences

Retrieved on: 
Wednesday, August 4, 2021
Health, Medicine, Health care quality, Medical terminology, Patient, Health care

NEW YORK, Aug. 4, 2021 /PRNewswire/ -- CipherHealth , a recognized leader and innovator in patient-centered communications, engagement, and insights for the nation's leading healthcare systems, today announced the next generation of its Patient Engagement Platform.

Key Points: 
  • NEW YORK, Aug. 4, 2021 /PRNewswire/ -- CipherHealth , a recognized leader and innovator in patient-centered communications, engagement, and insights for the nation's leading healthcare systems, today announced the next generation of its Patient Engagement Platform.
  • "It's clear that yesterday's engagement strategies no longer meet the changing dynamics of the industry," said CipherHealth Chief Executive Officer Jake Pyles.
  • This allows patients to more efficiently and automatically manage their own appointment schedules, helping reduce care gaps while increasing patient satisfaction.
  • CipherHealth is an award-winning digital patient engagement company committed to enhancing communication and coordination throughout the care continuum.

AMI Partners with LifeSign To Provide the Status COVID-19/Flu A&B Test for Upcoming Respiratory Season

Retrieved on: 
Tuesday, August 3, 2021
Medicine, Coronaviridae, Clinical medicine, Medical tests, Medical terminology, Nasopharyngeal swab, Respiratory therapy, Rapid diagnostic test, COVID-19, Severe acute respiratory syndrome, DiaSorin, Curative

Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.

Key Points: 
  • Gainesville, Aug. 03, 2021 (GLOBE NEWSWIRE) -- This years upcoming respiratory season presents new uncertainty and risk on the heels of the COVID-19 pandemic.
  • said Samatha Young, Head of Global Sales at AMI .
  • The LifeSign Status COVID-19 Flu A&B rapid test is a qualitative assay for the simultaneous detection of influenza A&B antigen and SARS CoV-2 antigen from nasopharyngeal swabs obtained from patients/Flu rapid combo test on the market.
  • As a leader in rapid diagnostics, LifeSign is excited and proud to partner with AMI.

Facedrive Becomes a Distributor of COVID-19 Rapid Antigen Tests for Workplace Screening in Small and Medium Sized Organizations

Retrieved on: 
Tuesday, August 3, 2021
Medical Supplies, Automotive, Online Retail, Technology, Professional services, Health, Small business, Infectious diseases, Retail, Alternative Vehicles, Fuels, Internet, Medical tests, Medical terminology, Articles, Rapid diagnostic test, E-government

Ultimately, the Company is aspiring to make the Government of Canadas rapid testing program accessible to all eligible businesses nationwide.

Key Points: 
  • Ultimately, the Company is aspiring to make the Government of Canadas rapid testing program accessible to all eligible businesses nationwide.
  • In the first month of Facedrives collaborative efforts with the Government of Canada, Facedrive will distribute rapid tests through its extensive partner network.
  • In all, registration, order, pick-up, delivery, training and reporting has been made quick and easy through the Facedrive Online Portal https://rapidtest.facedrive.com/ .
  • As our economy begins to safely reopen, rapid resting and workplace screening will support small businesses and help them recover quicker.

Graves' Disease Market Insight, Epidemiology and Market Research Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Genetics, Pharmaceutical, Health, Articles, Medicine, Medical terminology, Thyroid disease, Actuarial science, Disease, Graves' disease, Epidemiology, Academic disciplines

The "Graves' Disease - Market Insight, Epidemiology and Market Forecast -2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Graves' Disease - Market Insight, Epidemiology and Market Forecast -2030" report has been added to ResearchAndMarkets.com's offering.
  • The Graves' Disease market report provides current treatment practices, emerging drugs, Graves' Disease market share of the individual therapies, current and forecasted Graves' Disease market Size from 2018 to 2030 segmented by seven major markets.
  • The Report also covers current Graves' Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
  • The Graves' Disease epidemiology division provide insights about historical and current Graves' Disease patient pool and forecasted trend for every seven major countries.

Lightbeam Health Solutions Partners with Surescripts to Promote Medication Adherence Across Populations

Retrieved on: 
Monday, August 2, 2021
Other Health, Software, Managed care, General Health, Internet, Pharmaceutical, Data management, Technology, Hospitals, Dental, Practice Management, Health, Health sciences, Health, Pharmacy, Medical terminology, Health care quality, Adherence, Clinical pharmacology, Lightbeam

Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, announces a new partnership with Surescripts, a nationwide health information network.

Key Points: 
  • Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, announces a new partnership with Surescripts, a nationwide health information network.
  • The Surescripts Medication History for Populations service will be available to Lightbeam clients through the partnership, adding valuable insights on top of the robust analytics already available within the Lightbeam platform.
  • Surescripts Medication History for Populations includes a newly launched patient notifications feature that provides real-time medication adherence alerts, including the ability to inform care teams when patients do not pick up prescribed medications.
  • Medication adherence is the single biggest issue around patient compliance, said Kent Locklear, MD, MBA, Chief Medical Officer of Lightbeam.

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study

Retrieved on: 
Monday, August 2, 2021
Health sciences, Health care, Life sciences, Adherence, Clinical pharmacology, Health care quality, Medical terminology, Pharmacy, Active ingredient

Aramchol meglumine contains the same active pharmaceutical ingredient (API) called Aramchol.

Key Points: 
  • Aramchol meglumine contains the same active pharmaceutical ingredient (API) called Aramchol.
  • Exposure with once daily (QD) 383mg Aramchol meglumine oral dosage corresponds to that obtained with the existing twice daily (BID) 300mg Aramchol free acid form which is currently being evaluated in the Phase 3 ARMOR study.
  • This allows future development of the QD regimen with a potential improvement in convenience and adherence".
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.

eMed™ Bolsters Airline Partnerships with Convenient COVID-19 Testing for International Travelers

Retrieved on: 
Thursday, July 29, 2021
Articles, Medicine, Medical tests, Medical terminology, Technology, Assistive technology, Telehealth, Walgreens, Rapid diagnostic test

Travelers can now visit their respective airlines website, eMed.com, or select Walgreens pharmacy locations to purchase a rapid antigen home test kit for COVID-19 that is administered through the eMed site.

Key Points: 
  • Travelers can now visit their respective airlines website, eMed.com, or select Walgreens pharmacy locations to purchase a rapid antigen home test kit for COVID-19 that is administered through the eMed site.
  • International travelers are looking for ways to stay safer and simplify their travel experience, said Dr. Patrice Harris, eMed Co-Founder and CEO.
  • This is a best-in-class approach for rapid testing of travelers returning to the skies.
  • eMed ( www.eMed.com ) is a telehealth company democratizing healthcare with a digital point-of-care platform that provides fast, easy and affordable at-home health care testing, supervised and guided online by eMed Certified Guides.

Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery

Retrieved on: 
Thursday, July 29, 2021
Abdominal pain, Adhesion, Medical terminology, Draft:PPP001

CARLSBAD, Calif. and SHANGHAI, China, July 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.

Key Points: 
  • These results demonstrate a strong efficacy profile in acceleration of the time to recover bowel function combined with a favorable safety and tolerability profile, said Tom Hallam, Ph.D., CEO of Palisade Bio.
  • Further, LB1148 has now shown statistically significant acceleration of return of bowel function in a Phase 2 study for cardiovascular surgery and in a Phase 2 study for GI surgery.
  • The Phase 2, multicenter, randomized, double-blind, parallel, placebo-controlled clinical trial was completed as part of a co-development agreement between Palisade Bio and Newsoara.
  • Palisade Bios innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

Retrieved on: 
Thursday, July 29, 2021
Medical devices, Health, Hospitals, Surgery, Clinical trials, Pharmaceutical, Medicine, Health sciences, Health care, Medical terminology, Antihemorrhagic, Shaving, Transfusion medicine, Hematology, Adhesion barrier, Hemostasis, Topical medication, Hemostat

PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.

Key Points: 
  • PerClot launches Baxter into the attractive hemostatic powder segment, while expanding our surgical offerings and complementing our recent acquisition of Seprafilm Adhesion Barrier.
  • The trial evaluated the safety and efficacy of PerClot in achieving intraoperative hemostasis compared to the control (a similar marketed hemostatic powder).
  • Combined use of PerClot PHS with other topical hemostatic agents has not been studied in controlled clinical trials.
  • This release includes forward-looking statements concerning a definitive agreement entered into by Baxter to acquire PerClot Polysaccharide Hemostatic System from CryoLife, including expectations regarding the financial impact and other benefits of such acquisition for Baxter.

Draper Develops Artificial Lung Technology with $4.9M U.S. Army Grant, Earns ASAIO Award

Retrieved on: 
Thursday, July 29, 2021
Medicine, Medical specialties, Medical terminology, Medical equipment, Membrane technology, Clinical medicine, Intensive care medicine, Extracorporeal membrane oxygenation, Artificial lung, Extracorporeal, Oxygen saturation

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire-PRWeb/ --Artificial lung assist devices have been called life-savers for people who suffer respiratory failure.

Key Points: 
  • CAMBRIDGE, Mass., July 29, 2021 /PRNewswire-PRWeb/ --Artificial lung assist devices have been called life-savers for people who suffer respiratory failure.
  • Draper has done just that, making advances in an artificial lung technology called extracorporeal membrane oxygenation, or ECMO.
  • The device can become clogged with blood clots, which diminishes the membrane's ability to transfer oxygen and CO2.
  • We provide unbiased assessments of technology or systems designed or recommended by other organizationscustom designed, as well as commercial-off-the-shelf.